David Moreno-Ramírez

Prof. Dr. David Moreno-Ramírez


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in European Journal of Cancer
Verified
Journal Article
Open access
Claus GarbeClaus Garbe
Claus Garbe
TATeresa Amaral
Teresa Amaral
KPKetty Peris
Ketty Peris
AHAxel Hauschild
Axel Hauschild
PAPetr Arenberger
Petr Arenberger
AEAlexander M.M. Eggermont
Alexander M.M. Eggermont
A unique collaboration of multidisciplinary experts from the European Dermatology Forum, the European Association of Dermato-Oncology and the European Organization for Research and Treatment of Cancer (EORTC) was formed to make recommendations on cutaneous melanoma diagnosis and treatment, based on systematic literature reviews and the experts' experience. Cutaneous melanomas are excised with 1- to 2-cm safety margins. Sentinel lymph node dissection shall be performed as a staging procedure in patients with tumour thickness ≥1.0 mm or ≥0.8 mm with additional histological risk factors, although there is as yet no clear survival benefit for this approach. Therapeutic decisions in stage III/IV patients should be primarily made by an interdisciplinary oncology team ("Tumor Board"). Adjuvant therapies in stage III/IV patients are primarily anti-PD-1, independent of mutational status, or dabrafenib plus trametinib for BRAF-mutant patients. In distant metastasis, either resected or not, systemic treatment is indicated. For first-line treatment, particularly in BRAF wild-type patients, immunotherapy with PD-1 antibodies alone or in combination with CTLA-4 antibodies shall be considered. In particular scenarios for patients with stage IV melanoma and a BRAF-V600 E/K mutation, first-line therapy with BRAF/MEK inhibitors can be offered as an alternative to immunotherapy. In patients with primary resistance to immunotherapy and harbouring a BRAF-V600 E/K mutation, this therapy shall be offered in second-line. Systemic therapy in stage III/IV melanoma is a rapidly changing landscape, and it is likely that these recommendations may change in the near future.

1 February 2020 in European Journal of Cancer
Verified
Journal Article
Closed access
Claus GarbeClaus Garbe
Claus Garbe
TATeresa Amaral
Teresa Amaral
KPKetty Peris
Ketty Peris
AHAxel Hauschild
Axel Hauschild
PAPetr Arenberger
Petr Arenberger
AEAlexander M.M. Eggermont
Alexander M.M. Eggermont

9 August 2012 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
EVEsther De Vries
Esther De Vries
MTM. Trakatelli
M. Trakatelli
DKD. Kalabalikis
D. Kalabalikis
LFL. Ferrandiz
L. Ferrandiz
ARA. Ruiz-De-Casas
A. Ruiz-De-Casas
OGon behalf of the EPIDERM Group
on behalf of the EPIDERM Group
Background During recent years numerous studies have suggested that personal and environmental factors might influence cancer development. Objectives To investigate environmental and personal characteristics associated with skin cancer risk. Methods A multicentre hospital‐based case–control study was performed in Finland, Germany, Greece, Italy, Malta, Poland, Scotland and Spain, including 409 patients with squamous cell carcinoma (SCC), 602 with basal cell carcinoma (BCC) and 360 with cutaneous malignant melanoma (CMM) and 1550 control persons. Exposures were assessed by questionnaires that were partly self‐administered, partly completed by dermatologists. Unconditional logistic regression modelling was used to assess associations including the influence of certain drugs and food items on skin cancer risk. Results The usual associations were observed for sun exposure and pigmentation characteristics, with chronic sun exposure being most strongly associated with SCC risk, and naevi and atypical naevi with CMM risk. Use of ciprofloxacin was associated with a decreased risk of BCC [odds ratio (OR) 0·33] and use of thiazide diuretics was associated with an increased risk of SCC (OR 1·66). Ciprofloxacin was also associated with SCC (OR 0·34) and thiazines with BCC (OR 2·04), but these associations lost significance after correction for multiple testing. Consumption of pomegranate, rich in antioxidants, was associated with decreased BCC and SCC risk, also after correcting for multiple testing. Recent experience of stressful events was associated with increased risk, particularly of CMM. Conclusions In this large case–control study from across Europe the expected associations were observed for known risk factors. Some new potential protective factors and potential risk factors were identified for consumption of certain food items, medication use and stress, which deserve further investigation in future studies.

1 April 2007 in Archives of Dermatology
Verified
Journal Article
Closed access
PDF file
DMDavid Moreno-Ramírez
David Moreno-Ramírez
LFLara Ferrandiz
Lara Ferrandiz
ANAdoracion Nieto-Garcia
Adoracion Nieto-Garcia
RCRafael Carrasco
Rafael Carrasco
PMPedro Moreno-Alvarez
Pedro Moreno-Alvarez
FCFrancisco M. Camacho
Francisco M. Camacho
Research from JAMA Dermatology — Store-and-Forward Teledermatology in Skin Cancer Triage — Experience and Evaluation of 2009 Teleconsultations

27 July 2023 in European Journal of Cancer
Verified
Journal Article
Open access
ASAlexandros Stratigos
Alexandros Stratigos
Claus GarbeClaus Garbe
Claus Garbe
Clio DessiniotiClio Dessinioti
Clio Dessinioti
CLCeleste Lebbe
Celeste Lebbe
AAAlexander van Akkooi
Alexander van Akkooi
PLPaul Lorigan
Paul Lorigan
In order to update recommendations on treatment, supportive care, education, and follow-up of patients with invasive cutaneous squamous cell carcinoma (cSCC), a multidisciplinary panel of experts from the European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF), the European Society for Radiotherapy and Oncology (ESTRO), the European Union of Medical Specialists (UEMS), the European Academy of Dermatology and Venereology (EADV), and the European Organisation of Research and Treatment of Cancer (EORTC) was formed. Recommendations were based on an evidence-based literature review, guidelines, and expert consensus. Treatment recommendations are presented for common primary cSCC (low risk, high risk), locally advanced cSCC, regional metastatic cSCC (operable or inoperable), and distant metastatic cSCC. For common primary cSCC, the first-line treatment is surgical excision with postoperative margin assessment or micrographically controlled surgery. Achieving clear surgical margins is the most important treatment consideration for patients with cSCCs amenable to surgery. Regarding adjuvant radiotherapy for patients with high-risk localised cSCC with clear surgical margins, current evidence has not shown significant benefit for those with at least one high-risk factor. Radiotherapy should be considered as the primary treatment for non-surgical candidates/tumours. For cSCC with cytologically or histologically confirmed regional nodal metastasis, lymph node dissection is recommended. For patients with metastatic or locally advanced cSCC who are not candidates for curative surgery or radiotherapy, anti-PD-1 agents are the first-line systemic treatment, with cemiplimab being the first approved systemic agent for advanced cSCC by the Food and Drugs Administration/European Medicines Agency. Second-line systemic treatments for advanced cSCC, include epidermal growth factor receptor inhibitors (cetuximab) combined with chemotherapy or radiotherapy. Multidisciplinary board decisions are mandatory for all patients with advanced cSCC, considering the risks of toxicity, the age and frailty of patients, and co-morbidities, including immunosuppression. Patients should be engaged in informed, shared decision-making on management and be provided with the best supportive care to improve symptom management and quality of life. The frequency of follow-up visits and investigations for subsequent new cSCC depends on underlying risk characteristics.

2 August 2005 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
DMDavid Moreno-Ramírez
David Moreno-Ramírez
FMF Camacho Martínez
F Camacho Martínez